Share |

Content about Pharmaceutical sciences

August 25, 2011

No one knows more about wasteful spending than the government, and healthcare is on top of most people’s list when it comes to wasteful spending. Since 2009 the focus has shifted towards bringing down the cost of healthcare spending.

August 16, 2011

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

August 9, 2011

The company has partnered with Teva Pharmaceutical Industries of Israel to develop Multikine.

Cel-Sci Corporation (NYSE AMEX: CVM)with headquarters in Vienna, Va.,posted a net loss for Q2 2011, nearly six times deeper than in the second quarter of 2010.

Losses were $3.11 Million in the three-months quarter ended June 30, 2011 compared to $601,124 in 2010.

Revenue in the second quarter came entirely from grants and totaled a small sum of $77,403.

The company's expenses grew to $4.85 Million from $3.4 Million.

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 6, 2014

Silver Spring-based United Therapeutics (NASDAQ: UTHR) finished off 2013 with a strong showing, collecting revenues of over $1.1 billion for the first time in its corporate history as well posting a net profit for the full-year 2013 and upbeat 2014 outlook.

February 28, 2014

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

February 28, 2014

Shareholders of Gaithersburg, Maryland-based GlycoMimetics Inc (NASDAQ:GLYC) are already enjoying 42 percent gains after the company went public in January. The stock started off at $8 per share and has climbed to a high of $13.37, achieved only yesterday.

There’s some speculation as to why the stock price jumped 21 percent on February 25th, rumors range from short interest to major news on the way.

February 6, 2012

United Therapeutics Corporation (NASDAQ: UTHR)said it received notice from a generic drug manufacturer that it intends to release a remanufactured form of one of Silver Spring-based company's core drugs called Remodulin.

Sandoz Inc, submitted a Paragraph IV Certification Notice Letter which United Therapeutics received on February 3, 2012. The letter states that the company has sent an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) also in Silver Spring.

August 8, 2011

biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Chairman and Chief Executive Officer, Ryuji Ueno, M.D., Ph.D., Ph.D., said in a statement during its second quarter 2011, financial results that the company has filed a marketing application in the U.K. for approval of its drug lubiprostone to treat chronic idiopathic constipation.

July 19, 2011

The agreement could mean another merger and acquisition for the region

Another area based biotechnology company has partnered with a company on the other side of the country, a much larger company, far, far away from here.

This time it's Rockville based Micromet, Inc.

Micromet, Inc labels itself as a biopharmaceutical company focused on finding treatments for cancer through commercialization of innovative antibody based therapies. The company traces its root back to 1993 in Munich, Germany where a small group of scientists set upon treating cancer via T cell based therapies.